UBS AM Portfolio holdings
UBS AM is the US asset manager of UBS and grew out of Brinson Partners, an investment firm founded by Gary Brinson and made independent in 1989. Swiss Bank Corporation bought Brinson Partners in 1994, and once the bank merged with UBS, its founder Gary Brinson, who had run Swiss Bank's asset management business, became chief investment officer of UBS Asset Management. In 2024 the business took in Credit Suisse Asset Management and two of its own units, UBS Hedge Fund Solutions and UBS O’Connor, though the O’Connor business was later sold. Its clients are mainly institutions such as retirement plans, government bodies, endowments and foundations.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
S&P Global
SPGI
|
+$205M |
| 2 |
Johnson & Johnson
JNJ
|
+$186M |
| 3 |
Honeywell
HON
|
+$177M |
| 4 |
Mondelez International
MDLZ
|
+$132M |
| 5 |
Alibaba
BABA
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$270M |
| 2 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$212M |
| 3 |
Citigroup
C
|
+$185M |
| 4 |
Booking.com
BKNG
|
+$104M |
| 5 |
Intuitive Surgical
ISRG
|
+$103M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.36% |
| 2 | Technology | 14.71% |
| 3 | Financials | 13.04% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Communication Services | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Microsoft
MSFT
$3.88T
| $1.87B | 2.11% |
36,468,268
-1,266,905
| -3% | -$65.8M |
2013 Q2
12 quarters
|
|
2
Apple
AAPL
$5.09T
| $1.77B | 2% |
74,171,764
-3,054,724
| -4% | -$75.9M |
2013 Q2
12 quarters
|
|
3
Meta Platforms (Facebook)
META
$1.62T
| $1.41B | 1.6% |
12,354,402
-700,513
| -5% | -$80.7M |
2013 Q2
12 quarters
|
|
|
4
Johnson & Johnson
JNJ
$667B
| $1.37B | 1.54% |
11,255,956
+1,633,647
| +17% | +$186M |
2013 Q2
12 quarters
|
|
5
Amazon
AMZN
$2.58T
| $1.31B | 1.48% |
36,607,960
-315,480
| -0.9% | -$10.7M |
2013 Q2
12 quarters
|
|
6
Alphabet (Google) Class A
GOOGL
$3.46T
| $1.22B | 1.38% |
34,622,860
-66,060
| -0.2% | -$2.42M |
2015 Q4
2 quarters
|
|
7
ExxonMobil
XOM
$763B
| $1.06B | 1.2% |
11,331,221
+243,426
| +2% | +$21.5M |
2013 Q2
12 quarters
|
|
8
Alphabet (Google) Class C
GOOG
$3.44T
| $925M | 1.05% |
26,723,960
-595,840
| -2% | -$21.4M |
2015 Q4
2 quarters
|
|
9
GE Aerospace
GE
$317B
| $916M | 1.04% |
6,072,193
-63,684
| -1% | -$9.29M |
2013 Q2
12 quarters
|
|
10
PepsiCo
PEP
$187B
| $832M | 0.94% |
7,854,989
+480,168
| +7% | +$49.5M |
2013 Q2
12 quarters
|
|
11
JPMorgan Chase
JPM
$901B
| $814M | 0.92% |
13,100,460
-68,246
| -0.5% | -$4.26M |
2013 Q2
12 quarters
|
|
12
AT&T
T
$144B
| $757M | 0.86% |
23,205,798
+619,701
| +3% | +$18.4M |
2013 Q2
12 quarters
|
|
13
Chevron
CVX
$462B
| $743M | 0.84% |
7,087,933
+29,865
| +0.4% | +$3M |
2013 Q2
12 quarters
|
|
14
Home Depot
HD
$328B
| $741M | 0.84% |
5,803,315
-380,961
| -6% | -$50.4M |
2013 Q2
12 quarters
|
|
15
Gilead Sciences
GILD
$214B
| $734M | 0.83% |
8,796,615
-217,946
| -2% | -$19.3M |
2013 Q2
12 quarters
|
|
16
Wells Fargo
WFC
$251B
| $697M | 0.79% |
14,720,004
+315,549
| +2% | +$15.4M |
2013 Q2
12 quarters
|
|
17
Visa
V
$774B
| $681M | 0.77% |
9,183,728
+586,165
| +7% | +$45.9M |
2013 Q2
12 quarters
|
|
|
AGN
18
DELISTED
Allergan plc
AGN
| $661M | 0.75% |
2,860,816
-371,331
| -11% | -$85.6M |
2013 Q2
12 quarters
|
|
19
Procter & Gamble
PG
$377B
| $657M | 0.74% |
7,761,242
+149,849
| +2% | +$12.3M |
2013 Q2
12 quarters
|
|
20
UnitedHealth
UNH
$366B
| $647M | 0.73% |
4,584,200
+159,543
| +4% | +$21.3M |
2013 Q2
12 quarters
|
|
21
Verizon
VZ
$186B
| $644M | 0.73% |
11,525,406
+401,182
| +4% | +$20.8M |
2013 Q2
12 quarters
|
|
22
Amgen
AMGN
$254B
| $598M | 0.68% |
3,930,676
+218,029
| +6% | +$33.9M |
2013 Q2
12 quarters
|
|
23
Berkshire Hathaway Class B
BRK.B
$1.17T
| $590M | 0.67% |
4,074,075
+396,229
| +11% | +$56.6M |
2013 Q2
12 quarters
|
|
24
Pfizer
PFE
$173B
| $587M | 0.66% |
17,581,810
+1,672
| +0% | +$53.4K |
2013 Q2
12 quarters
|
|
|
CELG
25
DELISTED
Celgene Corp
CELG
| $551M | 0.62% |
5,586,581
-26,251
| -0.5% | -$2.72M |
2013 Q2
12 quarters
|
|
Similar funds
UBS AM's Q2 2016 Portfolio in Review
As of Q2 2016, UBS AM held 2,695 positions worth $88.5B, up 2.6% from $86.2B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
UBS AM's Q2 2016 filing shows 65 new, 1,198 increased, 577 reduced and 89 closed positions. Its largest new stake was S&P Global: 1,914,020 shares worth $205M. The largest sale was MCGRAW-HILL FINANCIAL INC COM, an estimated $270M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- UBS AM's largest Q2 2016 buy was S&P Global: 1,914,020 shares worth $205M.
- UBS AM added most to Johnson & Johnson in Q2 2016, an estimated $186M increase.
- UBS AM's biggest Q2 2016 reduction was Citigroup, cutting an estimated $185M.
- UBS AM fully exited MCGRAW-HILL FINANCIAL INC COM in Q2 2016, selling an estimated $270M.
- UBS AM's ten largest holdings make up 14% of its $88.5B portfolio in Q2 2016.
- UBS AM opened 65 new positions and closed 89 in Q2 2016.
- UBS AM's portfolio value rose 2.6% quarter-over-quarter to $88.5B.
Based on UBS AM's 13F filing for Q2 2016, filed 9 Aug 2016.